181 related articles for article (PubMed ID: 20584002)
21. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
23. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
Ozkaya A; Alkin Z; Yazici AT; Demirok A
Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
[TBL] [Abstract][Full Text] [Related]
25. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
26. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
27. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.
Park YG; Roh YJ
BMC Ophthalmol; 2015 Dec; 15():182. PubMed ID: 26691185
[TBL] [Abstract][Full Text] [Related]
28. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
29. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
34. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
36. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
38. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M; Itagaki K
Jpn J Ophthalmol; 2016 Jan; 60(1):42-50. PubMed ID: 26498642
[TBL] [Abstract][Full Text] [Related]
39. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
40. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
